Carla L Alves

7PUBLICATIONS
14CO-AUTHORS
Molecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 17, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.

Carla L Alves, Leena Karimi, Mikkel G Terp

|Jul 25, 2025
Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells.

Benedetta Policastro, Nikoline Nissen, Carla L Alves

|Mar 11, 2023
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.

Carla L Alves, Henrik J Ditzel

|Aug 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Carla L Alves, Sidse Ehmsen, Mikkel G Terp

|Jan 05, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.

Sanne Løkkegaard, Daniel Elias, Carla L Alves

|Jun 21, 2018
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.

Carla L Alves, Daniel Elias, Maria B Lyng

Pageof 2

Frequent Collaborators

6 joint publications

Henrik J Ditzel

3 joint publications

Martin Bak

3 joint publications

Elgene Lim

2 joint publications

Sidse Ehmsen